1o4i › Citations

Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.

Lange G, Lesuisse D, Deprez P, Schoot B, Loenze P, Bénard D, Marquette JP, Broto P, Sarubbi E, Mandine E
J Med Chem 46 5184-95 (2003)

Cited: 26 times
EuropePMC logo PMID: 14613321

Abstract

Results from a novel approach which uses protein crystallography for the screening of a low affinity inhibitor fragment library are analyzed by comparing the X-ray structures with bound fragments to the structures with the corresponding full length inhibitors. The screen for new phospho-tyrosine mimics binding to the SH2 domain of (pp60)src was initiated because of the limited cell penetration of phosphates. Fragments in our library typically had between 6 and 30 atoms and included compounds which had either millimolar activity in a Biacore assay or were suggested by the ab initio design program LUDI but had no measurable affinity. All identified fragments were located in the phospho-tyrosine pocket. The most promising fragments were successfully used to replace the phospho-tyrosine and resulted in novel nonpeptidic high affinity inhibitors. The significant diversity of successful fragments is reflected in the high flexibility of the phospho-tyrosine pocket. Comparison of the X-ray structures shows that the presence of the H-bond acceptors and not their relative position within the pharmacophore are essential for fragment binding and/or high affinity binding of full length inhibitors. The X-ray data show that the fragments are recognized by forming a complex H-bond network within the phospho-tyrosine pocket of SH2. No fragment structure was found in which this H-bond network was incomplete, and any uncompensated H-bond within the H-bond network leads to a significant decrease in the affinity of full length inhibitors. No correlation between affinity and fragment binding was found for these polar fragments and hence affinity-based screening would have overlooked some interesting starting points for inhibitor design. In contrast, we were unable to identify electron density for hydrophobic fragments, confirming that hydrophobic interactions are important for inhibitor affinity but of minor importance for ligand recognition. Our results suggest that a screening approach using protein crystallography is particularly useful to identify universal fragments for the conserved hydrophilic recognition sites found in target families such as SH2 domains, phosphatases, kinases, proteases, and esterases.

Articles - 1o4i mentioned but not cited (1)

  1. The Mechanism and Experimental Validation of Forsythoside A in the Treatment of Male Infertility Were Analyzed Based on Network Pharmacology and Molecular Docking. Ma Z, Liu X, Lu H, Li H, Gao R, Wen R, Tang Z, Yin H, He Y, Yang H. Evid Based Complement Alternat Med 2022 7723358 (2022)


Reviews citing this publication (9)

  1. A decade of fragment-based drug design: strategic advances and lessons learned. Hajduk PJ, Greer J. Nat Rev Drug Discov 6 211-219 (2007)
  2. Fragment-based lead discovery. Rees DC, Congreve M, Murray CW, Carr R. Nat Rev Drug Discov 3 660-672 (2004)
  3. A new strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound-target interactions. Huber W. J Mol Recognit 18 273-281 (2005)
  4. Survey of the year 2003 commercial optical biosensor literature. Rich RL, Myszka DG. J Mol Recognit 18 1-39 (2005)
  5. Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery. Hall DR, Kozakov D, Whitty A, Vajda S. Trends Pharmacol Sci 36 724-736 (2015)
  6. 4-Hydroxyphenylpyruvate dioxygenase inhibitors in combination with safeners: solutions for modern and sustainable agriculture. Ahrens H, Lange G, Müller T, Rosinger C, Willms L, van Almsick A. Angew Chem Int Ed Engl 52 9388-9398 (2013)
  7. Dehydroamino acids: chemical multi-tools for late-stage diversification. Bogart JW, Bowers AA. Org Biomol Chem 17 3653-3669 (2019)
  8. The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography. Gill A, Cleasby A, Jhoti H. Chembiochem 6 506-512 (2005)
  9. Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors. Jha V, Macchia M, Tuccinardi T, Poli G. Cancers (Basel) 12 E2327 (2020)

Articles citing this publication (16)

  1. Functional site profiling and electrostatic analysis of cysteines modifiable to cysteine sulfenic acid. Salsbury FR, Knutson ST, Poole LB, Fetrow JS. Protein Sci 17 299-312 (2008)
  2. A new small-molecule Stat3 inhibitor. McMurray JS. Chem Biol 13 1123-1124 (2006)
  3. Superbinder SH2 domains act as antagonists of cell signaling. Kaneko T, Huang H, Cao X, Li X, Li C, Voss C, Sidhu SS, Li SS. Sci Signal 5 ra68 (2012)
  4. Can free energy calculations be fast and accurate at the same time? Binding of low-affinity, non-peptide inhibitors to the SH2 domain of the src protein. Chipot C, Rozanska X, Dixit SB. J Comput Aided Mol Des 19 765-770 (2005)
  5. Ligand deconstruction: Why some fragment binding positions are conserved and others are not. Kozakov D, Hall DR, Jehle S, Luo L, Ochiana SO, Jones EV, Pollastri M, Allen KN, Whitty A, Vajda S. Proc Natl Acad Sci U S A 112 E2585-94 (2015)
  6. Constraining binding hot spots: NMR and molecular dynamics simulations provide a structural explanation for enthalpy-entropy compensation in SH2-ligand binding. Ward JM, Gorenstein NM, Tian J, Martin SF, Post CB. J Am Chem Soc 132 11058-11070 (2010)
  7. Identification of novel fragment compounds targeted against the pY pocket of v-Src SH2 by computational and NMR screening and thermodynamic evaluation. Taylor JD, Gilbert PJ, Williams MA, Pitt WR, Ladbury JE. Proteins 67 981-990 (2007)
  8. In silico fragment-based discovery of DPP-IV S1 pocket binders. Rummey C, Nordhoff S, Thiemann M, Metz G. Bioorg Med Chem Lett 16 1405-1409 (2006)
  9. Crystal structures of a high-affinity macrocyclic peptide mimetic in complex with the Grb2 SH2 domain. Phan J, Shi ZD, Burke TR, Waugh DS. J Mol Biol 353 104-115 (2005)
  10. Functional and structural characterization of the kinase insert and the carboxy terminal domain in VEGF receptor 2 activation. Manni S, Kisko K, Schleier T, Missimer J, Ballmer-Hofer K. FASEB J 28 4914-4923 (2014)
  11. Interaction of the non-phosphorylated peptide G7-18NATE with Grb7-SH2 domain requires phosphate for enhanced affinity and specificity. Gunzburg MJ, Ambaye ND, Del Borgo MP, Pero SC, Krag DN, Wilce MC, Wilce JA. J Mol Recognit 25 57-67 (2012)
  12. Purification, crystallization, small-angle X-ray scattering and preliminary X-ray diffraction analysis of the SH2 domain of the Csk-homologous kinase. Gunn NJ, Gorman MA, Dobson RC, Parker MW, Mulhern TD. Acta Crystallogr Sect F Struct Biol Cryst Commun 67 336-339 (2011)
  13. Dissecting the Influence of Protein Flexibility on the Location and Thermodynamic Profile of Explicit Water Molecules in Protein-Ligand Binding. Yang Y, Lill MA. J Chem Theory Comput 12 4578-4592 (2016)
  14. Hit clustering can improve virtual fragment screening: CDK2 and PARP1 case studies. Zeifman AA, Stroylov VS, Novikov FN, Stroganov OV, Zakharenko AL, Khodyreva SN, Lavrik OI, Chilov GG. J Mol Model 18 2553-2566 (2012)
  15. Conformation-dependent ligand hot spots in the spliceosomal RNA helicase BRR2. Vester K, Metz A, Huber S, Loll B, Wahl MC. Acta Crystallogr D Struct Biol 79 304-317 (2023)
  16. Investigations into Simplified Analogues of the Herbicidal Natural Product (+)-Cornexistin. Steinborn C, Tancredi A, Habiger C, Diederich C, Kramer J, Reingruber AM, Laber B, Freigang J, Lange G, Schmutzler D, Machettira A, Besong G, Magauer T, Barber DM. Chemistry 29 e202300199 (2023)


Quick links